

Kidney Disease Study for Membranous Nephropathy



The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is conducting a research study to evaluate the safety and effectiveness of Rituximab plus Cyclosporine in the treatment of Idiopathic Membranous Nephropathy (IMN).

You may be eligible to participate if you:

- are an adult at least 18 years of age.
- have been diagnosed with membranous nephropathy based on a kidney biopsy.
- have a large amount of protein in your urine (called the "Nephrotic syndrome")

Studies are conducted at the NIH Clinical Center in Bethesda, Maryland. There is no cost for study-related medications or tests received. Travel assistance may be provided.

For more information please call toll free:

1-800-411-1222

TTY: 1-866-411-1010

Se habla español

www.clinicaltrials.gov

Refer to study # **09-DK-0223**

Department of Health and Human Services
National Institutes of Health



National Institute
of Diabetes
and Digestive
and Kidney Diseases

